Amgen's Phase 3 Sjögren's win; Novartis' $900M radioligand deal
Phase 3positivedazodalibepPositive
AI Analysis
Summary
Amgen announced a Phase 3 trial success for dazodalibep in Sjögren's syndrome from its Horizon acquisition, while Novartis completed a $900 million radioligand deal.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
Phase 3 trial success in Sjögren's syndrome
Importance:8/10
Sentiment:
0.80
Phase_3_successCD40_ligand_antagonistSjögren's_syndromeAmgen_acquisitionradioligand_dealNovartis
Read the original article
Published by Endpoints News on September 22, 2026 3:29 PM